Cargando…

Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding

An antibody format, termed Fab-dsFv, has been designed for clinical indications that require monovalent target binding in the absence of direct Fc receptor (FcR) binding while retaining substantial serum presence. The variable fragment (Fv) domain of a humanized albumin-binding antibody was fused to...

Descripción completa

Detalles Bibliográficos
Autores principales: Davé, Emma, Adams, Ralph, Zaccheo, Oliver, Carrington, Bruce, Compson, Joanne E., Dugdale, Sarah, Airey, Michael, Malcolm, Sarah, Hailu, Hanna, Wild, Gavin, Turner, Alison, Heads, James, Sarkar, Kaushik, Ventom, Andrew, Marshall, Diane, Jairaj, Mark, Kopotsha, Tim, Christodoulou, Louis, Zamacona, Miren, Lawson, Alastair D., Heywood, Sam, Humphreys, David P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058625/
https://www.ncbi.nlm.nih.gov/pubmed/27532598
http://dx.doi.org/10.1080/19420862.2016.1210747
_version_ 1782459268266459136
author Davé, Emma
Adams, Ralph
Zaccheo, Oliver
Carrington, Bruce
Compson, Joanne E.
Dugdale, Sarah
Airey, Michael
Malcolm, Sarah
Hailu, Hanna
Wild, Gavin
Turner, Alison
Heads, James
Sarkar, Kaushik
Ventom, Andrew
Marshall, Diane
Jairaj, Mark
Kopotsha, Tim
Christodoulou, Louis
Zamacona, Miren
Lawson, Alastair D.
Heywood, Sam
Humphreys, David P.
author_facet Davé, Emma
Adams, Ralph
Zaccheo, Oliver
Carrington, Bruce
Compson, Joanne E.
Dugdale, Sarah
Airey, Michael
Malcolm, Sarah
Hailu, Hanna
Wild, Gavin
Turner, Alison
Heads, James
Sarkar, Kaushik
Ventom, Andrew
Marshall, Diane
Jairaj, Mark
Kopotsha, Tim
Christodoulou, Louis
Zamacona, Miren
Lawson, Alastair D.
Heywood, Sam
Humphreys, David P.
author_sort Davé, Emma
collection PubMed
description An antibody format, termed Fab-dsFv, has been designed for clinical indications that require monovalent target binding in the absence of direct Fc receptor (FcR) binding while retaining substantial serum presence. The variable fragment (Fv) domain of a humanized albumin-binding antibody was fused to the C-termini of Fab constant domains, such that the VL and VH domains were individually connected to the Cκ and CH1 domains by peptide linkers, respectively. The anti-albumin Fv was selected for properties thought to be desirable to ensure a durable serum half-life mediated via FcRn. The Fv domain was further stabilized by an inter-domain disulfide bond. The bispecific format was shown to be thermodynamically and biophysically stable, and retained good affinity and efficacy to both antigens simultaneously. In in vivo studies, the serum half-life of Fab-dsFv, 2.6 d in mice and 7.9 d in cynomolgus monkeys, was equivalent to Fab'-PEG.
format Online
Article
Text
id pubmed-5058625
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-50586252016-10-24 Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding Davé, Emma Adams, Ralph Zaccheo, Oliver Carrington, Bruce Compson, Joanne E. Dugdale, Sarah Airey, Michael Malcolm, Sarah Hailu, Hanna Wild, Gavin Turner, Alison Heads, James Sarkar, Kaushik Ventom, Andrew Marshall, Diane Jairaj, Mark Kopotsha, Tim Christodoulou, Louis Zamacona, Miren Lawson, Alastair D. Heywood, Sam Humphreys, David P. MAbs Report An antibody format, termed Fab-dsFv, has been designed for clinical indications that require monovalent target binding in the absence of direct Fc receptor (FcR) binding while retaining substantial serum presence. The variable fragment (Fv) domain of a humanized albumin-binding antibody was fused to the C-termini of Fab constant domains, such that the VL and VH domains were individually connected to the Cκ and CH1 domains by peptide linkers, respectively. The anti-albumin Fv was selected for properties thought to be desirable to ensure a durable serum half-life mediated via FcRn. The Fv domain was further stabilized by an inter-domain disulfide bond. The bispecific format was shown to be thermodynamically and biophysically stable, and retained good affinity and efficacy to both antigens simultaneously. In in vivo studies, the serum half-life of Fab-dsFv, 2.6 d in mice and 7.9 d in cynomolgus monkeys, was equivalent to Fab'-PEG. Taylor & Francis 2016-08-17 /pmc/articles/PMC5058625/ /pubmed/27532598 http://dx.doi.org/10.1080/19420862.2016.1210747 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Report
Davé, Emma
Adams, Ralph
Zaccheo, Oliver
Carrington, Bruce
Compson, Joanne E.
Dugdale, Sarah
Airey, Michael
Malcolm, Sarah
Hailu, Hanna
Wild, Gavin
Turner, Alison
Heads, James
Sarkar, Kaushik
Ventom, Andrew
Marshall, Diane
Jairaj, Mark
Kopotsha, Tim
Christodoulou, Louis
Zamacona, Miren
Lawson, Alastair D.
Heywood, Sam
Humphreys, David P.
Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding
title Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding
title_full Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding
title_fullStr Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding
title_full_unstemmed Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding
title_short Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding
title_sort fab-dsfv: a bispecific antibody format with extended serum half-life through albumin binding
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058625/
https://www.ncbi.nlm.nih.gov/pubmed/27532598
http://dx.doi.org/10.1080/19420862.2016.1210747
work_keys_str_mv AT daveemma fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT adamsralph fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT zaccheooliver fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT carringtonbruce fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT compsonjoannee fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT dugdalesarah fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT aireymichael fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT malcolmsarah fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT hailuhanna fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT wildgavin fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT turneralison fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT headsjames fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT sarkarkaushik fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT ventomandrew fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT marshalldiane fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT jairajmark fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT kopotshatim fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT christodouloulouis fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT zamaconamiren fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT lawsonalastaird fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT heywoodsam fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding
AT humphreysdavidp fabdsfvabispecificantibodyformatwithextendedserumhalflifethroughalbuminbinding